Literature DB >> 27156888

Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.

Subbiah Pugazhenthi1, Limei Qin2, P Hemachandra Reddy3.   

Abstract

Cognitive decline in chronic diabetic patients is a less investigated topic. Diabetes and obesity are among the modifiable risk factors for Alzheimer's disease (AD), the most common form of dementia. Studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation that are observed in these disorders. Advanced glycation end products generated by chronic hyperglycemia and their receptor RAGE provide critical links between diabetes and AD. Peripheral inflammation observed in obesity leads to insulin resistance and type 2 diabetes. Although the brain is an immune-privileged organ, cross-talks between peripheral and central inflammation have been reported. Damage to the blood brain barrier (BBB) as seen with aging can lead to infiltration of immune cells into the brain, leading to the exacerbation of central inflammation. Neuroinflammation, which has emerged as an important cause of cognitive dysfunction, could provide a central mechanism for aging-associated ailments. To further add to these injuries, adult neurogenesis that provides neuronal plasticity is also impaired in the diabetic brain. This review discusses these molecular mechanisms that link obesity, diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy. Published by Elsevier B.V.

Entities:  

Keywords:  Advanced glycation end products; Alzheimer's disease; Diabetes; Inflammation; Mitochondria; Obesity; Oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 27156888      PMCID: PMC5344771          DOI: 10.1016/j.bbadis.2016.04.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  138 in total

Review 1.  Glucolipotoxicity: fuel excess and beta-cell dysfunction.

Authors:  Vincent Poitout; R Paul Robertson
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

2.  Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.

Authors:  Weijing Cai; Jaime Uribarri; Li Zhu; Xue Chen; Shobha Swamy; Zhengshan Zhao; Fabrizio Grosjean; Calogera Simonaro; George A Kuchel; Michal Schnaider-Beeri; Mark Woodward; Gary E Striker; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

Review 3.  Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus.

Authors:  Rizwanul Haque; Aamir Nazir
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

4.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study.

Authors:  Rachel A Whitmer; Erica P Gunderson; Elizabeth Barrett-Connor; Charles P Quesenberry; Kristine Yaffe
Journal:  BMJ       Date:  2005-04-29

5.  Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity.

Authors:  Marciane Milanski; Giovanna Degasperi; Andressa Coope; Joseane Morari; Raphael Denis; Dennys E Cintra; Daniela M L Tsukumo; Gabriel Anhe; Maria E Amaral; Hilton K Takahashi; Rui Curi; Helena C Oliveira; José B C Carvalheira; Silvana Bordin; Mário J Saad; Lício A Velloso
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

6.  SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes.

Authors:  Takeshi Yoshizaki; Jill C Milne; Takeshi Imamura; Simon Schenk; Noriyuki Sonoda; Jennie L Babendure; Juu-Chin Lu; Jesse J Smith; Michael R Jirousek; Jerrold M Olefsky
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

7.  Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

Authors:  Miles C Miller; Rosemarie Tavares; Conrad E Johanson; Virginia Hovanesian; John E Donahue; Liliana Gonzalez; Gerald D Silverberg; Edward G Stopa
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

8.  Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study.

Authors:  Kai-Chen Wang; Lin-Chung Woung; Ming-Tsu Tsai; Chih-Ching Liu; Ying-Hwa Su; Chung-Yi Li
Journal:  Neuroepidemiology       Date:  2012-05-05       Impact factor: 3.282

9.  Rising midlife obesity will worsen future prevalence of dementia.

Authors:  Binod Nepal; Laurie J Brown; Kaarin J Anstey
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

10.  Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes.

Authors:  Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Erin Moshier; James Godbold; Mary Sano; Derek Leroith; Sterling Johnson; Rachel Preiss; Keren Koifman; Hadas Hoffman; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more
  118 in total

Review 1.  Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer's Disease?

Authors:  Sudhanshu P Raikwar; Sachin M Bhagavan; Swathi Beladakere Ramaswamy; Ramasamy Thangavel; Iuliia Dubova; Govindhasamy Pushpavathi Selvakumar; Mohammad Ejaz Ahmed; Duraisamy Kempuraj; Smita Zaheer; Shankar Iyer; Asgar Zaheer
Journal:  Mol Neurobiol       Date:  2018-05-24       Impact factor: 5.590

Review 2.  Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Authors:  Ramesh Kandimalla; Vani Thirumala; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-08-25       Impact factor: 5.187

Review 3.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Gray matter structural networks are associated with cardiovascular risk factors in healthy older adults.

Authors:  Shahrzad Kharabian Masouleh; Frauke Beyer; Leonie Lampe; Markus Loeffler; Tobias Luck; Steffi G Riedel-Heller; Matthias L Schroeter; Michael Stumvoll; Arno Villringer; A Veronica Witte
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

5.  Sceletium tortuosum may delay chronic disease progression via alkaloid-dependent antioxidant or anti-inflammatory action.

Authors:  A C Bennett; A Van Camp; V López; C Smith
Journal:  J Physiol Biochem       Date:  2018-03-09       Impact factor: 4.158

6.  Magnetic resonance assessment of the cerebral alterations associated with obesity development.

Authors:  Blanca Lizarbe; Basilio Campillo; Irene Guadilla; Pilar López-Larrubia; Sebastián Cerdán
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-23       Impact factor: 6.200

7.  Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.

Authors:  Yane Costa Chaves; Karina Genaro; José Alexandre Crippa; Joice Maria da Cunha; Janaína Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2021-01-19       Impact factor: 3.584

Review 8.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

9.  Can Diabetes Be Controlled by Lifestyle Activities?

Authors:  P Hemachandra Reddy
Journal:  Curr Res Diabetes Obes J       Date:  2017-03-20

Review 10.  Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction.

Authors:  María Arnoriaga-Rodríguez; José Manuel Fernández-Real
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.